1
|
Kropp AE, Nishihori M, Izumi T, Goto S, Yokoyama K, Saito R. Hormone Concentration Measurement in Intracranial Dural Arteriovenous Fistulae. World Neurosurg 2024; 185:e451-e460. [PMID: 38367858 DOI: 10.1016/j.wneu.2024.02.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2023] [Revised: 02/08/2024] [Accepted: 02/09/2024] [Indexed: 02/19/2024]
Abstract
OBJECTIVE Intracranial dural arteriovenous fistulae (DAVFs) represent a subset of cerebral vascular malformations associated with significant morbidity and mortality. In Japan, DAVF exhibits sex-based differences in anatomical distribution, with female predominance in the cavernous sinus (CS) and male predominance in the transverse sinus (TS). Nevertheless, the pathophysiology of DAVF is not fully understood, and hormonal influences are hypothesized to play a role in its development. This study aimed to investigate changes in the concentrations of sex steroid hormones between intracranial and peripheral sampling sites in patients with CS- and TS-DAVF. METHODS We recruited 19 patients with CS-DAVF (n = 12) and TS-DAVF (n = 7) in this study. Blood hormone measurements were obtained from peripheral and jugular bulb samples during endovascular intervention. Hormone concentrations were analyzed using enzyme-linked immunosorbent assay kits, and statistical analyses were performed. RESULTS Our study revealed a higher prevalence of CS-DAVF in females and TS-DAVF in males, which is consistent with previous studies. Estradiol concentration was significantly lower in the jugular bulb compared with in the periphery in both patients with CS- and TS-DAVF. This decrease in estradiol was observed irrespective of the patient's sex and independent of follicle-stimulating hormone levels. CONCLUSIONS These findings indicate a local decrease in estradiol levels within the intracranial vasculature of patients with DAVF. This suggests a potential multifactorial role of estradiol in the pathomechanism of DAVFs, warranting further investigation to understand its influence on DAVF formation and potential targeted therapies, thereby enhancing patient outcomes.
Collapse
Affiliation(s)
- Asuka Elisabeth Kropp
- Department of Neurosurgery, Nagoya University of Graduate School of Medicine, Showa-ku, Nagoya Aichi, Japan
| | - Masahiro Nishihori
- Department of Neurosurgery, Nagoya University of Graduate School of Medicine, Showa-ku, Nagoya Aichi, Japan.
| | - Takashi Izumi
- Department of Neurosurgery, Nagoya University of Graduate School of Medicine, Showa-ku, Nagoya Aichi, Japan
| | - Shunsaku Goto
- Department of Neurosurgery, Nagoya University of Graduate School of Medicine, Showa-ku, Nagoya Aichi, Japan
| | - Kinya Yokoyama
- Department of Neurosurgery, Nagoya University of Graduate School of Medicine, Showa-ku, Nagoya Aichi, Japan
| | - Ryuta Saito
- Department of Neurosurgery, Nagoya University of Graduate School of Medicine, Showa-ku, Nagoya Aichi, Japan
| |
Collapse
|
2
|
Kurisu K, Osanai T, Morishima Y, Ito M, Uchino H, Sugiyama T, Fujimura M. Systemic immune-inflammation index in dural arteriovenous fistula: a feasible biomarker reflecting its clinical characteristics. Acta Neurochir (Wien) 2024; 166:180. [PMID: 38627314 DOI: 10.1007/s00701-024-06075-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2024] [Accepted: 04/05/2024] [Indexed: 04/19/2024]
Abstract
PURPOSE The systemic immune-inflammation index (SII), a marker of systemic inflammation, can be calculated using peripheral blood tests. Although the SII has been reported as a feasible biomarker in various cerebrovascular diseases, no studies have explored in dural arteriovenous fistula (DAVF). A retrospective cohort study was performed to test whether the SII reflects the clinical characteristics of DAVF and whether this index could serve as a feasible biomarker. METHODS This study included 28 patients who underwent endovascular treatment (39 sessions) for DAVF between 2014 and 2023. The SII was calculated using the following formula: platelet count multiplied by neutrophil count divided by lymphocyte count. We investigated the correlation between the SII and various clinical characteristics of DAVF, including symptom manifestation, and digital subtraction angiography findings. Additionally, we compared pre- and post-endovascular treatment changes in the SII. RESULTS A significantly higher SII was observed in patients with multiple lesions, clinical symptoms (particularly aggressive symptoms), pseudophelebitic pattern (PPP), and sinus occlusion. Multivariate regression analysis revealed that the presence of symptoms (coefficient 270.9, P = 0.021) and PPP (coefficient 272.4, P = 0.017) were independent factors contributing to SII elevation. Notably, following endovascular treatment, there was a significant decrease in the elevated SII in patients whose symptoms resolved (P = 0.039) and where the DAVF was angiographically cured (P = 0.012). CONCLUSION Elevation of the SII in patients with advanced DAVF and its decrease following endovascular treatment suggests that the SII reflects the disease condition and indicates its potential as a promising biomarker.
Collapse
Affiliation(s)
- Kota Kurisu
- Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
| | - Toshiya Osanai
- Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Yutaka Morishima
- Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Masaki Ito
- Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Haruto Uchino
- Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Taku Sugiyama
- Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Miki Fujimura
- Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| |
Collapse
|
3
|
Jia DT, Jacobs CS, Tang M, Shaibani A, Lukas RV. The Spinal Dural Arteriovenous Fistula in a Patient With Metastatic Renal Cell Carcinoma. Cureus 2021; 13:e15303. [PMID: 34221759 PMCID: PMC8237924 DOI: 10.7759/cureus.15303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Spinal dural arteriovenous fistula (SDAVF) is an elusive and underdiagnosed disease. Congestive myelopathy occurs from increased venous pressure transmitted by the fistula between a radiculomeningeal artery and the spinal venous plexus. While its cause remains unknown, associations between SDAVF and hyper-vascular states have been reported. We present the first documented case report of a de novo SDAVF diagnosis in a patient with active renal cell carcinoma (RCC) metastasis to the spinal epidural space and review the literature.
Collapse
Affiliation(s)
- Dan Tong Jia
- Neurology, Northwestern University, Feinberg School of Medicine, Chicago, USA
| | - Caitlin S Jacobs
- Neurology, Northwestern University, Feinberg School of Medicine, Chicago, USA
| | - Mengxuan Tang
- Neurology, Northwestern University, Feinberg School of Medicine, Chicago, USA
| | - Ali Shaibani
- Neuroradiology, Northwestern University, Feinberg School of Medicine, Chicago, USA
| | - Rimas V Lukas
- Neuro-Oncology, Northwestern University, Feinberg School of Medicine, Chicago, USA
| |
Collapse
|
4
|
Bhogal P, AlMatter M, Hellstern V, Bäzner H, Ganslandt O, Henkes H, Aguilar Pérez M. High-Grade Dural Arteriovenous Fistulas : Use of Kaneka ED Coils with the Marathon Microcatheter for Transvenous Coil Embolization. Clin Neuroradiol 2018; 29:653-660. [PMID: 30167712 DOI: 10.1007/s00062-018-0724-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Accepted: 08/13/2018] [Indexed: 10/28/2022]
Abstract
BACKGROUND Dural arteriovenous fistulas (DAVF) are commonly encountered lesions that can be treated both transvenously, transarterially or using a combined approach. OBJECTIVE Transvenous coil embolization of DAVF is a recognized treatment option but can be challenging. In this context this article presents clinical experience using the Kaneka ED10 ExtraSoft coils in combination with the Marathon microcatheter to treat high grade DAVF. The physical properties of these coils and the microcatheter were also determined. MATERIAL AND METHODS All patients with high grade DAVF treated with the Marathon and the Kaneka ED COIL ∞10 ExtraSoft coils were retrospectively identified. The clinical presentation, location, grade of the lesion, clinical and radiological follow-up data were recorded. Bench side studies were performed to determine the physical properties of the Marathon catheter in comparison to the SL10 and Headway Duo as well the maximum width of the Kaneka pusher wire in comparison to Hypersoft, Target and Axium Prime coils. RESULTS A total of 8 patients with 9 DAVF with 3 Cognard 3 and 6 Cognard 4 lesions were identified. All the DAVF's were occluded either at the end of the procedure or on follow-up imaging. On bench side tests the Marathon microcatheter had the most flexible distal tip and distal shaft in comparison to the SL10 and Headway Duo. The proximal shaft of the Marathon was stiffer than the SL10. The Kaneka ED COIL ∞10 ExtraSoft had the smallest distal width and were the only coils tested that could be deployed through a Marathon microcatheter. CONCLUSION The combination of the Marathon microcatheter and Kaneka ED COIL ∞10 ExtraSoft is useful for the treatment of high grade DAVF.
Collapse
Affiliation(s)
- P Bhogal
- Neuroradiological Clinic, Neurocenter, Klinikum Stuttgart, Kriegsbergstraße 60, 70174, Stuttgart, Germany. .,Neurological Clinic, Neurocenter, Klinikum Stuttgart, Stuttgart, Germany.
| | - M AlMatter
- Neuroradiological Clinic, Neurocenter, Klinikum Stuttgart, Kriegsbergstraße 60, 70174, Stuttgart, Germany
| | - V Hellstern
- Neuroradiological Clinic, Neurocenter, Klinikum Stuttgart, Kriegsbergstraße 60, 70174, Stuttgart, Germany
| | - H Bäzner
- Neurological Clinic, Neurocenter, Klinikum Stuttgart, Stuttgart, Germany
| | - O Ganslandt
- Neurosurgical Clinic, Neurocenter, Klinikum Stuttgart, Stuttgart, Germany
| | - H Henkes
- Neuroradiological Clinic, Neurocenter, Klinikum Stuttgart, Kriegsbergstraße 60, 70174, Stuttgart, Germany.,Medical Faculty, University Duisburg-Essen, Essen, Germany
| | - M Aguilar Pérez
- Neuroradiological Clinic, Neurocenter, Klinikum Stuttgart, Kriegsbergstraße 60, 70174, Stuttgart, Germany
| |
Collapse
|
5
|
Radiosurgery reduces plasma levels of angiogenic factors in brain arteriovenous malformation patients. Brain Res Bull 2018; 140:220-225. [PMID: 29752992 DOI: 10.1016/j.brainresbull.2018.05.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Revised: 04/19/2018] [Accepted: 05/07/2018] [Indexed: 11/20/2022]
Abstract
PURPOSE Aberrant expression of angiogenic factors has been anecdotally documented in brain arteriovenous malformation (AVM) nidus vessels; however, no data is available on the effect of radiosurgery on the levels of angiogenic factors in AVM patients. We sought to determine the plasma contents of VEGF, TGF-β, Ang-2 and bFGF in 28 brain AVM patients at baseline and post radiosurgery and further analyzed the relationship between plasma contents of these angiogenic factors with clinicopathologic variables of these patients. METHODS We enrolled brain AVM patients who underwent Cyberknife radiosurgery at our hospital between January 2014 and December 2015. Brain AVM was confirmed by cerebral angiography and radiosurgery was performed with Cyberknife irradiation. Plasma contents of VEGF, TGF-β, Ang-2 and bFGF were analyzed using commercially available enzyme-linked immunoassay (ELISA) kits. RESULTS The baseline plasma VEGF content was 222.63 pg/mL (range 43.25-431.25 pg/mL). At three months post surgery, there was a significant -34.29% decline in plasma VEGF content versus baseline (P = 0.000). Furthermore, the median baseline plasma VEGF levels were higher in brain AVM with a nidus volume ≥ 10 cm3) than those with a nidus volume < 10 cm3 [median(IQR) 293.5 (186.5,359.25) vs. 202 (59.75, 270.75) pg/mL, P = 0.057]. The baseline plasma TGF-β content was 556.17 pg/mL (range 44.44-1486.11 pg/mL) and there was a significant -27.47% decline in plasma TGF-β content at 3 months post radiosurgery versus baseline (P = 0.015). Moreover, the baseline plasma ANG-2 content was 214.27 pg/mL (range 77.14-453.76 pg/mL). There was an immediate and significant -12.47% decline in plasma ANG-2 content post surgery versus baseline (P = 0.002). At three months post surgery, the plasma ANG-2 content still remained significantly depressed versus baseline (P = 0.002). In addition, the baseline plasma bFGF content was 9.17 pg/mL (range 3.67-36.78 pg/mL). No significant difference in plasma bFGF content was observed immediately post surgery and 3 months post surgery versus baseline (P = 0.05). CONCLUSIONS Radiosurgery for brain AVM patients significantly reduced the plasma levels of angiogenic factors. The plasma angiogenic factors may be candidate markers for aberrant agniogenesis of brain AVM and patient response to radiosurgery.
Collapse
|
6
|
Bhogal P, Yeo LL, Henkes H, Krings T, Söderman M. The role of angiogenesis in dural arteriovenous fistulae: the story so far. Interv Neuroradiol 2018; 24:450-454. [PMID: 29562862 DOI: 10.1177/1591019918764090] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Intracranial dural arteriovenous fistulae are a commonly encountered pathology that can present with a variety of different clinical symptoms. Although there is a significant body of work relating to the natural history and treatment of dural arteriovenous fistulae the exact underlying pathogenesis remains elusive. Various different pathogenetic models have been put forward but there is now a growing body of evidence implicating angiogenesis and the involvement of angiogenetic factors. In this review we attempt to show how the various animal and human studies performed over the past two decades have contributed to the proposed hypothesis on the development of dural arteriovenous fistulae.
Collapse
Affiliation(s)
- Pervinder Bhogal
- 1 Neuroradiological Clinic, Klinikum Stuttgart, Stuttgart, Germany.,2 Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
| | - Leonard L Yeo
- 2 Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden.,3 Division of Neurology, Department of Medicine, National University Health System, Singapore
| | - Hans Henkes
- 1 Neuroradiological Clinic, Klinikum Stuttgart, Stuttgart, Germany
| | - Timo Krings
- 4 Department of Neuroradiology, Toronto Western Hospital and University Health Network, Toronto, Canada
| | - Michael Söderman
- 2 Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
7
|
Renieri L, Michelozzi C, Brinjikji W, Darcout J, Guenego A, Vukasinovic I, Tall P, Bonneville F, Januel AC, Cognard C. PTA Stent of Dural Sinuses in Brain DAVF : A Report of 4 Cases. Clin Neuroradiol 2017; 29:331-339. [PMID: 29243076 DOI: 10.1007/s00062-017-0652-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2017] [Accepted: 11/24/2017] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND PURPOSE Type I and IIa dural arteriovenous fistulas (DAVFs) have a low hemorrhagic risk, but are often the cause of debilitating tinnitus that requires treatment. While Onyx® and PHIL™ (Precipitating hydrophobic injectable liquid) transarterial embolization represent the first endovascular option, there are occasional cases where performing angioplasty and stenting of the affected sinus may lead to satisfactory results. MATERIAL AND METHODS We retrospectively analyzed four consecutive cases of patients with DAVF-induced pulsatile tinnitus secondary to type I and II DAVFs who were treated with angioplasty and stenting of the sinus only. All the patients had clinical and radiological long-term follow-up. RESULTS We noticed a significant radiological and clinical improvement in all the cases. Of the patients two were completely cured at follow-up with eradication of the neurological symptoms as well as the fistula, one was retreated with Onyx® for a very small residual shunt despite having no more tinnitus, and one showed improvement in venous drainage (from type IIa+b to type I fistula) without resolution of the fistula. CONCLUSION In cases of type I and II DAVFs associated with sinus stenosis, angioplasty and stenting alone seem to be safe and effective. This treatment probably compresses the venules within the sinus walls, promoting thrombosis of the shunts thus solving the underlying cause of the fistula.
Collapse
Affiliation(s)
- Leonardo Renieri
- Department of Neuroradiology, Service de Neuroradiologie Diagnostique et Thérapeutique du CHU de Toulouse, University Hospital of Toulouse, Place du Dr Baylac, TSA 40031, 31059, Toulouse, France. .,Department of Medical Imaging, Division of Neuroradiology, Toronto Western Hospital, University Health Network & University of Toronto, 399 Bathurst Street, McL Wing, 3rd Floor, Room 438, M5T2S8, Toronto, ON, Canada.
| | - Caterina Michelozzi
- Department of Neuroradiology, Service de Neuroradiologie Diagnostique et Thérapeutique du CHU de Toulouse, University Hospital of Toulouse, Place du Dr Baylac, TSA 40031, 31059, Toulouse, France
| | - Waleed Brinjikji
- Department of Medical Imaging, Division of Neuroradiology, Toronto Western Hospital, University Health Network & University of Toronto, 399 Bathurst Street, McL Wing, 3rd Floor, Room 438, M5T2S8, Toronto, ON, Canada
| | - Jean Darcout
- Department of Neuroradiology, Service de Neuroradiologie Diagnostique et Thérapeutique du CHU de Toulouse, University Hospital of Toulouse, Place du Dr Baylac, TSA 40031, 31059, Toulouse, France
| | - Adrien Guenego
- Department of Neuroradiology, Service de Neuroradiologie Diagnostique et Thérapeutique du CHU de Toulouse, University Hospital of Toulouse, Place du Dr Baylac, TSA 40031, 31059, Toulouse, France
| | - Ivan Vukasinovic
- Department of Neuroradiology, Service de Neuroradiologie Diagnostique et Thérapeutique du CHU de Toulouse, University Hospital of Toulouse, Place du Dr Baylac, TSA 40031, 31059, Toulouse, France
| | - Philippe Tall
- Department of Neuroradiology, Service de Neuroradiologie Diagnostique et Thérapeutique du CHU de Toulouse, University Hospital of Toulouse, Place du Dr Baylac, TSA 40031, 31059, Toulouse, France
| | - Fabrice Bonneville
- Department of Neuroradiology, Service de Neuroradiologie Diagnostique et Thérapeutique du CHU de Toulouse, University Hospital of Toulouse, Place du Dr Baylac, TSA 40031, 31059, Toulouse, France
| | - Anne-Christine Januel
- Department of Neuroradiology, Service de Neuroradiologie Diagnostique et Thérapeutique du CHU de Toulouse, University Hospital of Toulouse, Place du Dr Baylac, TSA 40031, 31059, Toulouse, France
| | - Christophe Cognard
- Department of Neuroradiology, Service de Neuroradiologie Diagnostique et Thérapeutique du CHU de Toulouse, University Hospital of Toulouse, Place du Dr Baylac, TSA 40031, 31059, Toulouse, France
| |
Collapse
|
8
|
Lee CC, Chen CJ, Chen SC, Yang HC, Lin CJ, Wu CC, Chung WY, Guo WY, Hung-Chi Pan D, Shiau CY, Wu HM. Gamma Knife surgery for clival epidural-osseous dural arteriovenous fistulas. J Neurosurg 2017. [PMID: 28621628 DOI: 10.3171/2017.1.jns161346] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Clival epidural-osseous dural arteriovenous fistula (DAVF) is often associated with a large nidus, multiple arterial feeders, and complex venous drainage. In this study the authors report the outcomes of clival epidural-osseous DAVFs treated using Gamma Knife surgery (GKS). METHODS Thirteen patients with 13 clival epidural-osseous DAVFs were treated with GKS at the authors' institution between 1993 and 2015. Patient age at the time of GKS ranged from 38 to 76 years (median 55 years). Eight DAVFs were classified as Cognard Type I, 4 as Type IIa, and 1 as Type IIa+b. The median treatment volume was 17.6 cm3 (range 6.2-40.3 cm3). The median prescribed margin dose was 16.5 Gy (range 15-18 Gy). Clinical and radiological follow-ups were performed at 6-month intervals. Patient outcomes after GKS were categorized as 1) complete improvement, 2) partial improvement, 3) stationary, and 4) progression. RESULTS All 13 patients demonstrated symptomatic improvement, and on catheter angiography 12 of the 13 patients had complete obliteration and 1 patient had partial obliteration. The median follow-up period was 26 months (range 14-186 months). The median latency period from GKS to obliteration was 21 months (range 8-186 months). There was no intracranial hemorrhage during the follow-up period, and no deaths occurred. Two adverse events were observed following treatment, and 2 patients required repeat GKS treatment with eventual complete obliteration. CONCLUSIONS Gamma Knife surgery offers a safe and effective primary or adjuvant treatment modality for complex clival epidural-osseous DAVFs. All patients in this case series demonstrated symptomatic improvement, and almost all patients attained complete obliteration.
Collapse
Affiliation(s)
- Cheng-Chia Lee
- Departments of1Neurosurgery.,4School of Medicine, National Yang-Ming University
| | - Ching-Jen Chen
- 6Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia
| | | | - Huai-Che Yang
- Departments of1Neurosurgery.,4School of Medicine, National Yang-Ming University
| | - Chung Jung Lin
- 2Radiology, and.,4School of Medicine, National Yang-Ming University
| | - Chih-Chun Wu
- 2Radiology, and.,4School of Medicine, National Yang-Ming University
| | - Wen-Yuh Chung
- Departments of1Neurosurgery.,4School of Medicine, National Yang-Ming University
| | - Wan-Yuo Guo
- 2Radiology, and.,4School of Medicine, National Yang-Ming University
| | - David Hung-Chi Pan
- Departments of1Neurosurgery.,5Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan; and
| | - Cheng-Ying Shiau
- 3Radiation Oncology, Taipei Veterans General Hospital.,4School of Medicine, National Yang-Ming University
| | - Hsiu-Mei Wu
- 2Radiology, and.,4School of Medicine, National Yang-Ming University
| |
Collapse
|
9
|
Pan DHC, Lee CC, Wu HM, Chung WY, Yang HC, Lin CJ. Gamma Knife radiosurgery for the management of intracranial dural arteriovenous fistulas. ACTA NEUROCHIRURGICA. SUPPLEMENT 2013; 116:113-9. [PMID: 23417468 DOI: 10.1007/978-3-7091-1376-9_18] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
BACKGROUND This report presents our 15-year experience with Gamma Knife radiosurgery (GKS) for the treatment of 321 patients with dural arteriovenous fistulas (DAVFs) in different locations. METHODS The most common locations of DAVFs were the cavernous sinus (206 cases) and transverse-sigmoid sinus (72 cases), which together accounted for 86.6 % of cases. In all, 54 patients had undergone embolization or surgery prior to radiosurgery, and the other patients underwent GKS as the primary treatment. During GKS, radiation was confined to the involved sinus wall, which was considered the true nidus of the DAVF. Target volume ranged from 0.8 to 52 cm(3). Marginal and maximum doses to the nidus ranged from 14 to 25 Gy and from 25 to 36 Gy, respectively. RESULTS The mean follow-up time was 28 months (range 2-149 months). In 264 of 321 patients (82 %) available for follow-up study, 173 (66 %) showed complete obliteration of DAVFs with symptomatic resolution, 87 (33 %) had partial obliteration, 2 (0.8 %) had stationary status, 1 (0.4 %) had progression, and 1 (0.4 %) died from a new hemorrhagic episode. Complications were found in only two (0.8 %) patients, one with venous hemorrhage and one with focal brain edema after GKS. CONCLUSIONS GKS is a safe, effective treatment for DAVFs. It provides a minimally invasive therapeutic option for patients who harbor less-aggressive DAVFs but who suffer from intolerable clinical symptoms. For some aggressive DAVFs with extensive venous hypertension or hemorrhage, multimodal treatment with combined embolization or surgery is necessary.
Collapse
Affiliation(s)
- David Hung-Chi Pan
- Department of Neurosurgery, Taipei Veterans General Hospital, No. 201 Shi-Pai Rd., Sec. 2, Taipei, Taiwan.
| | | | | | | | | | | |
Collapse
|
10
|
S Miyachi E, Izumi T, Matsubara N, Naito T, Haraguchi K, Wakabayashi T. Mechanism of the formation of dural arteriovenous fistula: the role of the emissary vein. Interv Neuroradiol 2011; 17:195-202. [PMID: 21696658 DOI: 10.1177/159101991101700209] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2010] [Accepted: 11/07/2010] [Indexed: 11/15/2022] Open
Abstract
Dural arteriovenous fistula (DAVF) can be separated into two types: DAVF which drains through an affected sinus (sinus type) and DAVF with direct reflux to the cortical vein (non-sinus type). The present report attempted to clarify the mechanism of formation and development of DAVF focusing on the emissary vein (EV) hypothesis.First, inflammation occurs at the penetrating point of the EV on the dura due to idiopathic or secondary causes. Local inflammatory reactions induce vessel dilatation and neovascularization, and subsequently create arteriovenous (AV) connections on the arteriole level. Although EV communicating with dural arteries might play a role as draining routes at first, they start to degrade due to compression of enlarged emissary arteries or to a hemodynamic shift to the drainage pathway of least resistance. Following the occlusion of drainage pathway through EV into the sinus or cortical veins may form, resulting in clinically detectable DAVF. The AV shunt then expands to the surrounding dura associated with recruitment of feeders from distant sites induced by expression of angiogenetic factors and a shift in the hemodynamic balance. In sinus type DAVF, the sinus is progressively compartmentalized and finally occludes due to thrombogenesis with activated coagulopathy or to hemodynamic hypertrophy of the sinus wall. This progression results in the mature, aggressive DAVF with drainage impairments. Previous mechanistic hypotheses focusing on sinus hypertension and sinus thromboses cannot explain the pathogenesis of non-sinus type of DAVF. Although the etiology of DAVF may be concerned by the thrombo-occlusive change of sinus, the unique theory presented in this report may enable an understanding of the common etiology of both types of DAVF.
Collapse
Affiliation(s)
- E S Miyachi
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, Japan.
| | | | | | | | | | | |
Collapse
|
11
|
Iizuka Y, Yamashiro Y, Suzuki M, Sumi Y, Oizumi H, Yoritaka A, Tanaka S. Possible role of local hypoxia in the de novo formation of dural and osteodural arteriovenous fistulas after encephalitis. A case report. Neuroradiol J 2008; 21:698-703. [PMID: 24257014 DOI: 10.1177/197140090802100515] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2008] [Accepted: 08/04/2008] [Indexed: 11/16/2022] Open
Abstract
A rare case of de novo formation of dural and osteodural arteriovenous fistulas after encephalitis is presented. We review and discuss the etiological angiogenetic factors and processes in intracranial dural arteriovenous fistulas formation. Local tissue hypoxia may have played a role in the initial step causing sprouting angiogenesis as the main pathogenesis of DAVFs formation.
Collapse
Affiliation(s)
- Y Iizuka
- Department of Radiology; Juntendo Urayasu Hospital, Juntendo University; Chiba, Japan -
| | | | | | | | | | | | | |
Collapse
|
12
|
Kim GH, Hahn DK, Kellner CP, Hickman ZL, Komotar RJ, Starke RM, Mack WJ, Mocco J, Solomon RA, Connolly ES. Plasma levels of vascular endothelial growth factor after treatment for cerebral arteriovenous malformations. Stroke 2008; 39:2274-9. [PMID: 18535271 DOI: 10.1161/strokeaha.107.512442] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE The role of abnormal angiogenesis in the formation and progression of cerebral arteriovenous malformations (AVMs) is unclear. Previous studies have demonstrated increased local expression of vascular endothelial growth factor (VEGF) in AVM tissue and increased circulating levels of VEGF in AVM patients. We sought to further investigate the role of VEGF in AVM pathophysiology by examining changes in plasma VEGF levels in patients undergoing treatment for AVMs. METHODS Three serial blood samples were obtained from 13 AVM patients undergoing treatment: (1) before any treatment, (2) 24 hours postresection, and (3) 30 days postresection. Plasma VEGF concentrations were measured via commercially available enzyme-linked immunosorbent assay (ELISA). For controls, blood samples were obtained from 29 lumbar laminectomy patients. RESULTS The mean plasma VEGF level in AVM patients at baseline was 36.08+/-13.02 pg/mL, significantly lower than that of the control group (80.52+/-14.02 pg/mL, P=0.028). Twenty-four hours postresection, plasma VEGF levels dropped to 20.09+/-4.54 pg/mL, then increased to 66.81+/-26.45 pg/mL 30 days later (P=0.048). The mean plasma VEGF concentration 30 days after resection was no longer significantly different from the control group (P=0.33). CONCLUSIONS Plasma VEGF levels in 13 AVM patients were unexpectedly lower than controls, dropped early after AVM resection, then significantly increased 30 days later. These results support the key role of abnormal angiogenesis in AVM pathophysiology and suggest that a disruption in systemic VEGF expression may contribute to the natural history of these lesions.
Collapse
Affiliation(s)
- Grace H Kim
- Department of Neurological Surgery, Columbia College of Physicians and Surgeons, Neurological Institute of New York, 630 W 168th St, Room 5-454, New York, NY 10032, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Drevs J, Schneider V. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. J Intern Med 2006; 260:517-29. [PMID: 17116002 DOI: 10.1111/j.1365-2796.2006.01727.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Recent findings about the pathomechanisms of tumour angiogenesis have led to new therapeutic options in the treatment of malignant tumours. During the development of anti-angiogenic drugs, reporting ranged from healing cancer to completely ineffective drugs. In 2003 the first anti-angiogenic drug was approved. Several anti-angiogenic drugs are still in the clinical phase of development. In contrast to identifying the maximal tolerable dose, determination of the optimal biological dose--reaching biological activity at lower doses--has become the main target in the early development of anti-angiogenic agents. This has been evaluated by different biomarker techniques. As a new standard in anti-tumour treatment, a better understanding of imaging in the treatment monitoring for anti-angiogenic agents is important. Studies of tumour angiogenesis by tissue sampling rely on invasive procedures, adequate sampling and painstaking estimation of histological microvessel density. Attempts to develop wound healing assays to correlate angiogenesis in wounds with angiogenesis in tumour have been made but are still considered invasive and correlation of healthy with malignant tissue is still of limited validity. Several soluble markers of tumour angiogenesis were detected in various malignant diseases and were evaluated for assessing their use as surrogate markers in tumour angiogenesis. Further, soluble markers were investigated for visualizing them as imaging tools. Combining both, new soluble markers and imaging techniques, developing anticancer drugs and monitoring of therapy success becomes a dynamic process in which finally the patients' individual response can be achieved soon. Time-consuming delays for anatomically based restaging procedures can be avoided. Characterization of soluble biomarkers as well as different imaging techniques such as ultrasound, computed tomography (CT), magnetic resonance imaging and positron emission tomography combined with or without CT are reviewed in this manuscript.
Collapse
Affiliation(s)
- J Drevs
- Tumorklinik Sanafontis, Freiburg, Germany.
| | | |
Collapse
|
14
|
Söderman M, Edner G, Ericson K, Karlsson B, Rähn T, Ulfarsson E, Andersson T. Gamma knife surgery for dural arteriovenous shunts: 25 years of experience. J Neurosurg 2006; 104:867-75. [PMID: 16776329 DOI: 10.3171/jns.2006.104.6.867] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Object
The aim of this study was to assess the clinical efficacy of gamma knife surgery (GKS) in the treatment of dural arteriovenous shunts (DAVSs).
Methods
From a database of more than 1600 patients with intracranial arteriovenous shunts that had been treated with GKS, the authors retrospectively and prospectively identified 53 patients with 58 DAVSs from the period between 1978 and 2003. Four patients were lost to follow-up evaluation and were excluded from the series. Thus, this study is based on the remaining 49 patients with 52 DAVSs. Thirty-six of the shunts drained into the cortical venous system, either directly or indirectly, and 22 of these were associated with intracranial hemorrhage on patient presentation. The mean prescription radiation dose was 22 Gy (range 10–28 Gy).
All patients underwent a clinical follow-up examination. In 41 cases of DAVS a follow-up angiography study was performed. At the 2-year follow-up visit, 28 cases (68%) had angiographically proven obliteration of the shunt and in another 10 cases (24%) there was significant flow regression. Three shunts remained unchanged.
There was one immediate minor complication related to the administration of radiation. Furthermore, one patient had a radiation-induced complication 10 years after treatment, although she recovered completely. There was one posterior fossa bleed 2 months after radiosurgery; a hematoma, as well as a lesion, was evacuated, and the patient recovered uneventfully. A second patient had an asymptomatic occipital hemorrhage approximately 6 months postradiosurgery.
The clinical outcome after GKS was significantly better than that in patients with naturally progressing shunts (p < 0.01, chi-square test); figures on the latter have been reported previously.
Conclusions
Gamma knife surgery is an effective treatment for DAVSs, with a low risk of complications. Major disadvantages of this therapy include the time elapsed before obliteration and the possibility that not all shunts will be obliterated. Cortical venous drainage from a DAVS, a risk factor for intracranial hemorrhage, is therefore a relative contraindication. Consequently, GKS can be used in the treatment of both benign DAVSs with subjectively intolerable bruit and aggressive DAVSs not responsive to endovascular treatment or surgery.
Collapse
Affiliation(s)
- Michael Söderman
- Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden.
| | | | | | | | | | | | | |
Collapse
|